These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

458 related items for PubMed ID: 30794891

  • 21. Molecular and Histopathological Characterization of the Tumor Immune Microenvironment in Advanced Stage of Malignant Pleural Mesothelioma.
    Patil NS, Righi L, Koeppen H, Zou W, Izzo S, Grosso F, Libener R, Loiacono M, Monica V, Buttigliero C, Novello S, Hegde PS, Papotti M, Kowanetz M, Scagliotti GV.
    J Thorac Oncol; 2018 Jan; 13(1):124-133. PubMed ID: 29079455
    [Abstract] [Full Text] [Related]

  • 22. Comparison of SP263 and 22C3 pharmDx assays to test programmed death ligand-1 (PD-L1) expression in surgically resected non-small cell lung cancer.
    Shigeta N, Murakami S, Yokose T, Isaka T, Shinada K, Nagashima T, Adachi H, Shigefuku S, Murakami K, Miura J, Kikunishi N, Watabe K, Saito H, Ito H.
    Thorac Cancer; 2024 Jun; 15(17):1343-1349. PubMed ID: 38698758
    [Abstract] [Full Text] [Related]

  • 23. PD-L1 expression associated with worse survival outcome in malignant pleural mesothelioma.
    Nguyen BH, Montgomery R, Fadia M, Wang J, Ali S.
    Asia Pac J Clin Oncol; 2018 Feb; 14(1):69-73. PubMed ID: 29105302
    [Abstract] [Full Text] [Related]

  • 24. Companion and Complementary Diagnostics-Focus on PD-L1 Expression Assays for PD-1/PD-L1 Checkpoint Inhibitors in Non-Small Cell Lung Cancer.
    Hersom M, Jørgensen JT.
    Ther Drug Monit; 2018 Feb; 40(1):9-16. PubMed ID: 29084031
    [Abstract] [Full Text] [Related]

  • 25. Trametinib plus 4-Methylumbelliferone Exhibits Antitumor Effects by ERK Blockade and CD44 Downregulation and Affects PD-1 and PD-L1 in Malignant Pleural Mesothelioma.
    Cho H, Matsumoto S, Fujita Y, Kuroda A, Menju T, Sonobe M, Kondo N, Torii I, Nakano T, Lara PN, Gandara DR, Date H, Hasegawa S.
    J Thorac Oncol; 2017 Mar; 12(3):477-490. PubMed ID: 27867002
    [Abstract] [Full Text] [Related]

  • 26. Efficacy and Safety of Avelumab Treatment in Patients With Advanced Unresectable Mesothelioma: Phase 1b Results From the JAVELIN Solid Tumor Trial.
    Hassan R, Thomas A, Nemunaitis JJ, Patel MR, Bennouna J, Chen FL, Delord JP, Dowlati A, Kochuparambil ST, Taylor MH, Powderly JD, Vaishampayan UN, Verschraegen C, Grote HJ, von Heydebreck A, Chin K, Gulley JL.
    JAMA Oncol; 2019 Mar 01; 5(3):351-357. PubMed ID: 30605211
    [Abstract] [Full Text] [Related]

  • 27. Comparison of PD-L1 immunohistochemistry assays and response to PD-1/L1 inhibitors in advanced non-small-cell lung cancer in clinical practice.
    Villaruz LC, Ancevski Hunter K, Kurland BF, Abberbock S, Herbst C, Dacic S.
    Histopathology; 2019 Jan 01; 74(2):269-275. PubMed ID: 30105871
    [Abstract] [Full Text] [Related]

  • 28. Tumour infiltrating lymphocytes and PD-L1 expression as potential predictors of outcome in patients with malignant pleural mesothelioma.
    Sobhani N, Roviello G, Pivetta T, Ianza A, Bonazza D, Zanconati F, Giudici F, Bottin C, Corona SP, Guglielmi A, Rizzardi C, Milione M, Cortale M, Confalonieri M, Generali D.
    Mol Biol Rep; 2019 Jun 01; 46(3):2713-2720. PubMed ID: 30840203
    [Abstract] [Full Text] [Related]

  • 29. Validation of PD-L1 clone 22C3 immunohistochemical stain on two Ventana DISCOVERY autostainer models: detailed protocols, test performance characteristics, and interobserver reliability analyses.
    Basu A, Chiriboga L, Narula N, Zhou F, Moreira AL.
    J Histotechnol; 2020 Dec 01; 43(4):174-181. PubMed ID: 33245263
    [Abstract] [Full Text] [Related]

  • 30. PD-L1 Assays 22C3 and SP263 are Not Interchangeable in Non-Small Cell Lung Cancer When Considering Clinically Relevant Cutoffs: An Interclone Evaluation by Differently Trained Pathologists.
    Munari E, Rossi G, Zamboni G, Lunardi G, Marconi M, Sommaggio M, Netto GJ, Hoque MO, Brunelli M, Martignoni G, Haffner MC, Moretta F, Pegoraro MC, Cavazza A, Samogin G, Furlan V, Mariotti FR, Vacca P, Moretta L, Bogina G.
    Am J Surg Pathol; 2018 Oct 01; 42(10):1384-1389. PubMed ID: 29901568
    [Abstract] [Full Text] [Related]

  • 31. A Harmonization Study for the Use of 22C3 PD-L1 Immunohistochemical Staining on Ventana's Platform.
    Neuman T, London M, Kania-Almog J, Litvin A, Zohar Y, Fridel L, Sandbank J, Barshak I, Vainer GW.
    J Thorac Oncol; 2016 Nov 01; 11(11):1863-1868. PubMed ID: 27664534
    [Abstract] [Full Text] [Related]

  • 32. Small Biopsies Misclassify up to 35% of PD-L1 Assessments in Advanced Lung Non-Small Cell Lung Carcinomas.
    Bigras G, Mairs S, Swanson PE, Morel D, Lai R, Izevbaye I.
    Appl Immunohistochem Mol Morphol; 2018 Nov 01; 26(10):701-708. PubMed ID: 30095468
    [Abstract] [Full Text] [Related]

  • 33. Programmed Death-Ligand 1 Immunohistochemistry Testing: A Review of Analytical Assays and Clinical Implementation in Non-Small-Cell Lung Cancer.
    Büttner R, Gosney JR, Skov BG, Adam J, Motoi N, Bloom KJ, Dietel M, Longshore JW, López-Ríos F, Penault-Llorca F, Viale G, Wotherspoon AC, Kerr KM, Tsao MS.
    J Clin Oncol; 2017 Dec 01; 35(34):3867-3876. PubMed ID: 29053400
    [Abstract] [Full Text] [Related]

  • 34. Association between PD-L1 expression and driver gene mutations in non-small cell lung cancer patients: correlation with clinical data.
    Karatrasoglou EA, Chatziandreou I, Sakellariou S, Stamopoulos K, Kavantzas N, Lazaris AC, Korkolopoulou P, Saetta AA.
    Virchows Arch; 2020 Aug 01; 477(2):207-217. PubMed ID: 31989260
    [Abstract] [Full Text] [Related]

  • 35. Equivalence of laboratory-developed test and PD-L1 IHC 22C3 pharmDx across all combined positive score indications.
    Vainer G, Huang L, Emancipator K, Nuti S.
    PLoS One; 2023 Aug 01; 18(6):e0285764. PubMed ID: 37267266
    [Abstract] [Full Text] [Related]

  • 36. Programmed Death-Ligand 1 Immunohistochemistry Assay Comparison Studies in NSCLC: Characterization of the 73-10 Assay.
    Grote HJ, Feng Z, Schlichting M, Helwig C, Ruisi M, Jin H, Scheuenpflug J, Gann CN, Su Z, Reck M, Vokes EE, Kerr KM.
    J Thorac Oncol; 2020 Aug 01; 15(8):1306-1316. PubMed ID: 32353599
    [Abstract] [Full Text] [Related]

  • 37. Expression of ALCAM (CD166) and PD-L1 (CD274) independently predicts shorter survival in malignant pleural mesothelioma.
    Inaguma S, Lasota J, Wang Z, Czapiewski P, Langfort R, Rys J, Szpor J, Waloszczyk P, Okoń K, Biernat W, Ikeda H, Schrump DS, Hassan R, Miettinen M.
    Hum Pathol; 2018 Jan 01; 71():1-7. PubMed ID: 28811252
    [Abstract] [Full Text] [Related]

  • 38. PD-L1 testing of non-small cell lung cancer using different antibodies and platforms: a Swiss cross-validation study.
    Savic S, Berezowska S, Eppenberger-Castori S, Cathomas G, Diebold J, Fleischmann A, Jochum W, Komminoth P, McKee T, Letovanec I, Jasarevic Z, Rössle M, Singer G, von Gunten M, Zettl A, Zweifel R, Soltermann A, Bubendorf L.
    Virchows Arch; 2019 Jul 01; 475(1):67-76. PubMed ID: 31127385
    [Abstract] [Full Text] [Related]

  • 39. Prognostic Role of Programmed Cell Death 1 Ligand 1 in Resectable Pleural Mesothelioma.
    Lee HS, Hamaji M, Palivela N, Jang HJ, Splawn T, Ramos D, Lee AK, Raghuram AC, Ramineni M, Amos CI, Ripley RT, Burt BM.
    Ann Thorac Surg; 2021 Nov 01; 112(5):1575-1583. PubMed ID: 33248997
    [Abstract] [Full Text] [Related]

  • 40. A Prospective Phase II Single-arm Study of Niraparib Plus Dostarlimab in Patients With Advanced Non-small-cell Lung Cancer and/or Malignant Pleural Mesothelioma, Positive for PD-L1 Expression and Germline or Somatic Mutations in the DNA Repair Genes: Rationale and Study Design.
    Passiglia F, Bironzo P, Righi L, Listì A, Arizio F, Novello S, Volante M, Scagliotti GV.
    Clin Lung Cancer; 2021 Jan 01; 22(1):e63-e66. PubMed ID: 32917522
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 23.